View Exam | PowerPak

1. Female sexual desire is most likely to be negatively affected by which one of the following:

A. Testosterone B. Bupropion C. Estrogen D. Antipsychotic drugs

2. Which one of the following is least likely to be affected by an antidepressant drug:

A. Sexual desire B. Sexual arousal C. Orgasm D. Resolution

3. When sexual complaints are accompanied by personal distress, the overall prevalence of any sexual disorder in women is:

A. 43% B. 32% C. 28% D. 12%

4. Although most clinical literature about female sexual dysfunction focuses on HSDD, why did the most recent Diagnostic and Statistical Manual of Mental Disorders (DSM5) combine sexual interest and arousal disorder together into one diagnostic category?

A. The prevalence of female sexual desire and arousal disorders is equal B. Unlike men, women do not move sequentially through desire, arousal, and orgasm, but have a more complex and overlapping set of symptoms C. The requirement of a 6-month duration of symptoms makes it impossible to separate desire and arousal disorders D. Psychological components, environmental factors, and medical conditions all can contribute to an inability to distinguish between desire and arousal difficulties

5. Which one of the following best describes why sildenafil is not considered a potential treatment for female sexual dysfunction:

A. Sildenafil failed in efficacy trials compared with placebo B. Sildenafil augments genital engorgement and response in women C. When compared with men, women experienced substantially more adverse effects from sildenafil D. Women with sexual arousal disorder usually have impaired clitoral engorgement

6. Which of the following is correct regarding flibanserin for female sexual dysfunction:

A. It was developed as a potential antidepressant since its serotonin agonist mechanism is similar to the selective serotonin reuptake inhibitor (SSRI) antidepressants B. The U.S. Food and Drug Administration (FDA) denied marketing approval in 2010 because of failed efficacy trials C. The FDA denied it marketing approval in 2013 because of concerns about safety and drug-drug interactions D. Its most common adverse effects include dizziness, constipation, and edema

7. The primary reason that testosterone preparations have not been approved for female sexual dysfunction is because

A. There are continuing concerns that available clinical trials do not adequately assess the long-term safety of testosterone treatment for women B. It has not been shown to consistently improve low desire and/or arousal C. Both the gel and patch formulations have not been shown capable of delivering the lower doses needed by women D. There is inadequate experience with the use of testosterone preparations in women

8. When a patient should be switched from paroxetine to a different antidepressant because of drug-induced sexual dysfunction, which one of the following would be best if the patient also has difficulty with fatigue and decreased energy:

A. Mirtazapine B. Bupropion C. Escitalopram D. Venlafaxine

9. Which one of the following is an effective management option for sertraline-induced sexual dysfunction in women:

A. Giving the patient occasional drug holidays if they are taking higher doses of an SSRI B. Augmenting with phosphodiesterase-5 (PDE-5) inhibitors like sildenafil C. Augmenting with ginkgo biloba D. Discontinuing sertraline and substituting either bupropion or mirtazapine

10. A woman, 42 years of age, comes to your pharmacy with a new prescription for fluoxetine. Which one of the following would not be recommended in her counseling for fluoxetine:

A. “Fluoxetine might cause changes in your sexual function. If so, contact your prescriber because it can be treated if it occurs.” B. “You may experience changes in sexual function from the fluoxetine. There are several ways your prescriber can treat the sexual dysfunction if it occurs to enable you to continue taking your antidepressant medication.” C. “Possible effective ways to manage sexual dysfunction from fluoxetine include switching to another drug or taking 2-day drug holiday occasionally.” D. “Do not lower the dose or stop the fluoxetine on your own, but make any changes together with your prescriber.”